Marengo Therapeutics is at the forefront of cancer treatment innovation, focusing on harnessing the body's immune system to create a robust and lasting response against tumors. The company has developed a unique approach to T cell activation by targeting specific Variable β (Vβ) chain variants of the T cell receptor (TCR). This method allows for the selective modulation of T cell subsets, particularly those found in tumor-infiltrating lymphocytes (TILs). Their STAR platform is designed to provide a dual boost to T cells, enhancing their function and response to tumors, particularly in antigen-rich environments. This platform has shown promising results in preclinical studies, demonstrating potent anti-tumor activity and the ability to expand a diverse population of effector memory T cells.

In addition to the STAR platform, Marengo has introduced the TriSTAR platform, which aims to address the challenges posed by "cold" tumors that typically exhibit low levels of immune cell infiltration. TriSTAR utilizes a novel class of T cell engagers that not only expand Vβ T cells but also direct them to these less immunogenic tumors, enhancing their anti-tumor efficacy. Both platforms leverage advanced antibody technology and a deep understanding of TCR biology to create therapies that are not only effective but also exhibit improved safety profiles by selectively activating a smaller fraction of the T cell compartment. This innovative approach positions Marengo Therapeutics as a leader in the development of next-generation immunotherapies for a wide range of cancers.

United States

Marengo Therapeutics, a clinical stage biotech company, is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.

Marengo Therapeutics

Company Details